Skip to main content
SpringerLink
Log in

Pain in the Cancer Survivor

  • Chapter
  • First Online:
Fundamentals of Cancer Pain Management

Part of the book series: Cancer Treatment and Research ((CTAR,volume 182))

Abstract

Recent decades have demonstrated significant strides in cancer screening, diagnostics and therapeutics. As such there have been dramatic changes in survival following a diagnosis of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Cancer Society (2020) Cancer facts and figures 2020

    Google Scholar 

  2. Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023–1075

    Article  PubMed  PubMed Central  Google Scholar 

  3. Arnold M, Rutherford MJ, Bardot A et al (2019) Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 20:1493–1505

    Article  PubMed  PubMed Central  Google Scholar 

  4. Brown M, Farquhar-Smith P (2017) Pain in cancer survivors; filling in the gaps. Br J Anaesth 119:723–736

    Article  CAS  PubMed  Google Scholar 

  5. Van Den Beuken-Van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ (2016) Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage Elsevier Inc 51:1070–90

    Google Scholar 

  6. Bluethmann SM, Mariotto AB, Rowland JH (2016) Anticipating the silver tsunami: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 25:1029–1036

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rees S (2016) The meaning of the term breast cancer survivor for young women living with a history of breast cancer in the UK. Eur J Surg Oncol 42:S238

    Article  Google Scholar 

  8. National Coalition for Cancer Survivorship (2020) NCCS mission (Internet). (cited 2020 Mar 17). Available from: https://www.canceradvocacy.org/about-us/our-mission/

  9. Macmillan Cancer Support Department of Health NHS Improvement (2013) Living with and beyond cancer: taking action to improve outcomes. London

    Google Scholar 

  10. Moser EC, Meunier F (2014) Cancer survivorship: a positive side-effect of more successful cancer treatment. Eur J Cancer, Suppl 12:1–4

    Article  Google Scholar 

  11. Sanson-Fisher R, Girgis A, Boyes A, Bonevski B, Burton L, Cook P (2000) The unmet supportive care needs of patients with cancer. Cancer 88:226–237

    Article  CAS  PubMed  Google Scholar 

  12. Koopman C, Angell K, Turner-Cobb JM et al (2001) Distress, coping, and social support among rural women recently diagnosed with primary breast cancer. Breast J 7:25–33

    Article  CAS  PubMed  Google Scholar 

  13. Ream E, Quennell A, Fincham L et al (2008) Supportive care needs of men living with prostate cancer in England: a survey. Br J Cancer 98:1903–1909

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Burg MA, Adorno G, Lopez EDS et al (2015) Current unmet needs of cancer survivors: analysis of open-ended responses to the American Cancer Society study of cancer survivors II. Cancer 121:623–630

    Article  PubMed  Google Scholar 

  15. Palmer SC, Demichele A, Schapira M et al (2016) Symptoms, unmet need, and quality of life among recent breast cancer survivors. J Community Support Oncol 14:299–306

    Article  Google Scholar 

  16. Lemay K, Wilson KG, Buenger U et al (2011) Fear of pain in patients with advanced cancer or in patients with chronic noncancer pain. Clin J Pain 27:116–124

    Article  PubMed  Google Scholar 

  17. Capelli G, De Vincenzo RI, Addamo A, Bartolozzi F, Braggio N, Scambia G (2002) Which dimensions of health-related quality of life are altered in patients attending the different gynecologic oncology health care settings? Cancer 95:2500–2507

    Article  PubMed  Google Scholar 

  18. Korfage IJ, Essink-Bot ML, Mols F, van de Poll-Franse L, Kruitwagen R, van Ballegooijen M (2009) Health-related quality of life in cervical cancer survivors: a population-based survey. Int J Radiat Oncol Biol Phys 73:1501–1509

    Article  PubMed  Google Scholar 

  19. Dinkel A, Herschbach P (2018) Fear of progression in cancer patients and survivors. Recent Results Cancer Res 210:13–33

    Article  PubMed  Google Scholar 

  20. Crist JV, Grunfeld EA (2013) Factors reported to influence fear of recurrence in cancer patients: a systematic review. Psychooncology 22:978–986

    Article  PubMed  Google Scholar 

  21. Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ (2001) Understanding the experience of pain in terminally ill patients. Lancet 357:1311–1315

    Article  CAS  PubMed  Google Scholar 

  22. Perentes JY, Duda DG, Jain RK (2009) Visualizing anti-tumor immune responses in vivo. Dis Model Mech 2:107–110

    Article  PubMed  PubMed Central  Google Scholar 

  23. Le Bitoux M-A, Stamenkovic I (2008) Tumor-host interactions: the role of inflammation. Histochem Cell Biol 130:1079–1090

    Article  CAS  PubMed  Google Scholar 

  24. Schmidt BL (2014) The neurobiology of cancer pain. Neuroscientist 20:546–562

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  CAS  PubMed  Google Scholar 

  26. DeBerardinis RJ, Chandel NS (2016) Fundamentals of cancer metabolism. Sci Adv 2:e1600200

    Google Scholar 

  27. Osthues T, Sisignano M (2019) Oxidized lipids in persistent pain states. Front Pharmacol 10:1147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Urch C (2004) The pathophysiology of cancer-induced bone pain: current understanding. Palliat Med 18:267–274

    Article  PubMed  Google Scholar 

  29. Blair JM, Zhou H, Seibel MJ, Dunstan CR (2006) Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3:41–49

    Article  CAS  PubMed  Google Scholar 

  30. Zheng Y, Zhou H, Dunstan CR, Sutherland RL, Seibel MJ (2013) The role of the bone microenvironment in skeletal metastasis. J Bone Oncol 2:47–57

    Article  PubMed  Google Scholar 

  31. Simmons CPL, MacLeod N, Laird BJA (2012) Clinical management of pain in advanced lung cancer. Clin Med Insights Oncol 6:331–346

    Article  PubMed  PubMed Central  Google Scholar 

  32. Mach DB, Rogers SD, Sabino MC et al (2002) Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 113:115–166

    Article  Google Scholar 

  33. Mantyh PW (2014) The neurobiology of skeletal pain. Eur J Neurosci 39:508–519

    Article  PubMed  PubMed Central  Google Scholar 

  34. Jimenez-Andrade JM, Bloom AP, Stake JI et al (2010) Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci 30:14649–14656

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Falk S, Dickenson AH (2014) Pain and nociception: mechanisms of cancer-induced bone pain. J Clin Oncol 32:1647–1654

    Article  CAS  PubMed  Google Scholar 

  36. Muralidharan A, Smith MT (2013) Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. Inflammopharmacology 21:339–363

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Slosky LM, BassiriRad NM, Symons AM et al (2016) The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain. Pain 157:2605–2616

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Honoré P, Schwei MJ, Rogers SD et al (2000) Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog Brain Res 129:389–397

    Article  PubMed  Google Scholar 

  39. Hansen RR, Vacca V, Pitcher T, Clark AK, Malcangio M (2016) Role of extracellular calcitonin gene-related peptide in spinal cord mechanisms of cancer-induced bone pain. Pain 157:666–676

    Article  CAS  PubMed  Google Scholar 

  40. Liu XD, Yang JJ, Fang D, Cai J, Wan Y, Xing GG (2014) Functional upregulation of Nav1.8 sodium channels on the membrane of dorsal root ganglia neurons contributes to the development of cancer-induced bone pain. PLoS One 9:e114623

    Google Scholar 

  41. Donovan-Rodriguez T, Dickenson AH, Urch CE (2004) Superficial dorsal horn neuronal responses and the emergence of behavioural hyperalgesia in a rat model of cancer-induced bone pain. Neurosci Lett 360:29–32

    Article  CAS  PubMed  Google Scholar 

  42. Guimarães-Pereira L, Farinha F, Azevedo L, Abelha F, Castro-Lopes J (2016) Persistent postoperative pain after cardiac surgery: incidence, characterization, associated factors and its impact in quality of life. Eur J Pain (United Kingdom) 20:1433–1442

    Google Scholar 

  43. Werner MU, Kongsgaard UE (2014) Defining persistent post-surgical pain: is an update required? Br J Anaesth 113:1–4

    Article  CAS  PubMed  Google Scholar 

  44. Cregg R, Anwar S, Farquhar-Smith P (2013) Persistent postsurgical pain. Curr Opin Support Palliat Care 7:144–152

    Article  PubMed  Google Scholar 

  45. Wang K, Yee C, Tam S et al (2018) Prevalence of pain in patients with breast cancer post-treatment: a systematic review. Breast 42:113–127

    Article  PubMed  Google Scholar 

  46. Høimyr H, Von Sperling ML, Rokkones KA et al (2012) Persistent pain after surgery for cutaneous melanoma. Clin J Pain 28:149–156

    Article  PubMed  Google Scholar 

  47. Johansen A, Romundstad L, Nielsen CS, Schirmer H, Stubhaug A (2012) Persistent postsurgical pain in a general population: prevalence and predictors in the Tromsø study. Pain 153:1390–1396

    Article  PubMed  Google Scholar 

  48. Haroutiunian S, Nikolajsen L, Finnerup NB, Jensen TS (2013) The neuropathic component in persistent postsurgical pain: a systematic literature review. Pain 154:95–102

    Article  PubMed  Google Scholar 

  49. Dualé C, Ouchchane L, Schoeffler P, Dubray C (2014) Neuropathic aspects of persistent postsurgical pain: a french multicenter survey with a 6-month prospective follow-up. J Pain 15(24):e1-24.e20

    Google Scholar 

  50. Peng Z, Li H, Zhang C, Qian X, Feng Z, Zhu S (2014) A retrospective study of chronic post-surgical pain following thoracic surgery: prevalence, risk factors, incidence of neuropathic component, and impact on qualify of life. PLoS One 9:e90014

    Google Scholar 

  51. Johansen A, Schirmer H, Nielsen CS, Stubhaug A (2016) Persistent post-surgical pain and signs of nerve injury: the Tromsø study. Acta Anaesthesiol Scand 60:380–392

    Article  CAS  PubMed  Google Scholar 

  52. Rogers ML, Henderson L, Mahajan RP, Duffy JP (2002) Preliminary findings in the neurophysiological assessment of intercostal nerve injury during thoracotomy. Eur J Cardio-thoracic Surg 21:298–301

    Article  CAS  Google Scholar 

  53. Maguire MF, Ravenscroft A, Beggs D, Duffy JP (2006) A questionnaire study investigating the prevalence of the neuropathic component of chronic pain after thoracic surgery. Eur J Cardio-thoracic Surg 29:800–805

    Article  Google Scholar 

  54. Maguire MF, Latter JA, Mahajan R, Beggs FD, Duffy JP (2006) A study exploring the role of intercostal nerve damage in chronic pain after thoracic surgery. Eur J Cardio-thoracic Surg 29:873–879

    Article  Google Scholar 

  55. Macdonald L, Bruce J, Scott NW, Smith WCS, Chambers WA (2005) Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer 92:225–230

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Andersen KG, Duriaud HM, Jensen HE, Kroman N, Kehlet H (2015) Predictive factors for the development of persistent pain after breast cancer surgery. Pain 156:2413–2422

    Article  PubMed  Google Scholar 

  57. Ferlay J, Soerjomataram I, Ervik M et al (2013) Cancer incidence and mortality worldwide. Int Agency Res Cancer, World Heal Organ 136:E359–E386

    Google Scholar 

  58. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30

    Article  PubMed  Google Scholar 

  59. Moo TA, Sanford R, Dang C, Morrow M (2018) Overview of breast cancer therapy. PET Clin 13:339–354

    Article  PubMed  PubMed Central  Google Scholar 

  60. Jung BF, Ahrendt GM, Oaklander AL, Dworkin RH (2003) Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain 104:1–13

    Article  PubMed  Google Scholar 

  61. Kalso E IV (2013) Persistent post-surgery pain: research agenda for mechanisms, prevention, and treatment. Br J Anaesth 111:9–12

    Article  CAS  PubMed  Google Scholar 

  62. Gärtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H (2009) Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA - J Am Med Assoc 302:1985–1992

    Article  Google Scholar 

  63. Katz J, Seltzer Z (2009) Transition from acute to chronic postsurgical pain: risk factors and protective factors. Expert Rev Neurother 9:723–744

    Article  PubMed  Google Scholar 

  64. Werner MU, Mjöbo HN, Nielsen PR, Rudin Å (2010) Prediction of postoperative pain: a systematic review of predictive experimental pain studies. Anesthesiology 112:1494–1502

    Article  PubMed  Google Scholar 

  65. Sipilä R, Estlander AM, Tasmuth T, Kataja M, Kalso E (2012) Development of a screening instrument for risk factors of persistent pain after breast cancer surgery. Br J Cancer 107:1459–1466

    Article  PubMed  PubMed Central  Google Scholar 

  66. Bruce J, Thornton AJ, Powell R et al (2014) Psychological, surgical, and sociodemographic predictors of pain outcomes after breast cancer surgery: a population-based cohort study. Pain 155:232–243

    Article  PubMed  Google Scholar 

  67. Meretoja TJ, Leidenius MHK, Tasmuth T, Sipilä R, Kalso E (2014) Pain at 12 months after surgery for breast cancer. JAMA - J Am Med Assoc 311:90–92

    Article  CAS  Google Scholar 

  68. Hoofwijk DMN, Fiddelers AAA, Peters ML et al (2015) Prevalence and predictive factors of chronic postsurgical pain and poor global recovery 1 year after outpatient surgery. Clin J Pain 31:1017–1025

    Article  PubMed  Google Scholar 

  69. Wang L, Guyatt GH, Kennedy SA et al (2016) Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ 188:E352–E361

    Article  PubMed  PubMed Central  Google Scholar 

  70. Meretoja TJ, Andersen KG, Bruce J et al (2017) Clinical prediction model and tool for assessing risk of persistent pain after breast cancer surgery. J Clin Oncol 35:1660–1667

    Article  PubMed  Google Scholar 

  71. Andreae MH, Andreae DA (2013) Regional anaesthesia to prevent chronic pain after surgery: a Cochrane systematic review and meta-analysis. Br J Anaesth 111:711–720

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Weinstein EJ, Levene JL, Cohen MS, et al. (2018) Local anaesthetics and regional anaesthesia versus conventional analgesia for preventing persistent postoperative pain in adults and children. Cochrane Database Syst Rev 2018 4:CD007105

    Google Scholar 

  73. Katz J, Weinrib A, Fashler SR et al (2015) The toronto general hospital transitional pain service: development and implementation of a multidisciplinary program to prevent chronic postsurgical pain. J Pain Res 12:695–702

    Article  Google Scholar 

  74. van Rijckevorsel DCM, de Vries M, Schreuder LTW, Wilder-Smith OHG, van Goor H (2015) Risk factors for chronic postsurgical abdominal and pelvic pain. Pain Manag 5:107–116

    Article  PubMed  Google Scholar 

  75. Gerbershagen HJ, Özgür E, Dagtekin O et al (2009) Preoperative pain as a risk factor for chronic post-surgical pain—six month follow-up after radical prostatectomy. Eur J Pain 13:1054–1061

    Article  PubMed  Google Scholar 

  76. Gerbershagen HJ, Dagtekin O, Rothe T et al (2009) Risk factors for acute and chronic postoperative pain in patients with benign and malignant renal disease after nephrectomy. Eur J Pain 13:853–860

    Article  PubMed  Google Scholar 

  77. Montes A, Roca G, Sabate S et al (2015) Genetic and clinical factors associated with chronic postsurgical pain after hernia repair, hysterectomy, and thoracotomy: a two-year multicenter cohort study. Anesthesiology 122:1123–1141

    Article  PubMed  Google Scholar 

  78. Joris JL, Georges MJ, Medjahed K et al (2015) Prevalence, characteristics and risk factors of chronic postsurgical pain after laparoscopic colorectal surgery: retrospective analysis. Eur J Anaesthesiol 32:712–717

    Article  PubMed  Google Scholar 

  79. VanDenKerkhof EG, Hopman WM, Reitsma ML et al (2012) Chronic pain, healthcare utilization, and quality of life following gastrointestinal surgery. Can J Anesth 59:670–680

    Article  PubMed  Google Scholar 

  80. Brandsborg B, Dueholm M, Nikolajsen L, Kehlet H, Jensen TS (2009) A prospective study of risk factors for pain persisting 4 months after hysterectomy. Clin J Pain 25:263–268

    Article  PubMed  Google Scholar 

  81. Brandsborg B, Nikolajsen L, Hansen CT, Kehlet H, Jensen TS (2007) Risk factors for chronic pain after hysterectomy: a nationwide questionnaire and database study. Anesthesiology 106:1003–1012

    Article  PubMed  Google Scholar 

  82. Beyaz SG, Özocak H, Ergönenç T, et al. (2016) Chronic postsurgical pain and neuropathic symptoms after abdominal hysterectomy: a silent epidemic. Med (United States) 95:e4484

    Google Scholar 

  83. Theunissen M, Peters ML, Schepers J et al (2016) Recovery 3 and 12 months after hysterectomy. Medicine (Baltimore) 95:23980

    Article  Google Scholar 

  84. Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R (2016) The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil 22:558–574

    Article  PubMed  PubMed Central  Google Scholar 

  85. Hockley JRF, Boundouki G, Cibert-Goton V, et al. (2014) Multiple roles for NaV1.9 in the activation of visceral afferents by noxious inflammatory, mechanical, and human disease-derived stimuli. Pain 155: 1962–75

    Google Scholar 

  86. Kolesnikov Y, Gabovits B, Levin A et al (2013) Chronic pain after lower abdominal surgery: do catechol-O-methyl transferase/opioid receptor μ-1 polymorphisms contribute? Mol Pain 9:19

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Lavand’homme P, De Kock M (2006) The use of intraoperative epidural or spinal analgesia modulates postoperative hyperalgesia and reduces residual pain after major abdominal surgery. Acta Anaesthesiol Belg 57 373–9

    Google Scholar 

  88. Bouman EA, Theunissen M, Bons SA et al (2014) Reduced incidence of chronic postsurgical pain after epidural analgesia for abdominal surgery. Pain Pract 14:E76-84

    Article  PubMed  Google Scholar 

  89. Peng L, Ren L, Qin P, Su M (2016) The impact of patient-controlled analgesia on prognosis of patients receiving major abdominal surgery. Minerva Anestesiol 82:827–838

    PubMed  Google Scholar 

  90. Pusceddu MM, Gareau MG (2018) Visceral pain: gut microbiota, a new hope? J Biomed Sci 25:73

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Verdú EF, Bercik P, Verma-Gandhu M et al (2006) Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55:182–190

    Article  PubMed  PubMed Central  Google Scholar 

  92. Aguilera M, Cerdà-Cuéllar M, Martínez V (2015) Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice. Gut Microbes 6:10–23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Rousseaux C, Thuru X, Gelot A et al (2007) Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 13:35–37

    Article  CAS  PubMed  Google Scholar 

  94. Savignac HM, Kiely B, Dinan TG, Cryan JF (2014) Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice. Neurogastroenterol Motil 26:1615–1627

    Article  CAS  PubMed  Google Scholar 

  95. Luczynski P, Tramullas M, Viola M, et al. (2017) Microbiota regulates visceral pain in the mouse. Elife 6:e25887

    Google Scholar 

  96. Walsh J, Griffin BT, Clarke G, Hyland NP (2018) Drug–gut microbiota interactions: implications for neuropharmacology. Br J Pharmacol 175:4415–4429

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Lederer AK, Pisarski P, Kousoulas L, Fichtner-Feigl S, Hess C, Huber R (2017) Postoperative changes of the microbiome: are surgical complications related to the gut flora? A systematic review. BMC Surg 17:125

    Article  PubMed  CAS  Google Scholar 

  98. Aardema H, Lisotto P, Kurilshikov A et al (2020) Marked changes in gut microbiota in cardio-surgical intensive care patients: a longitudinal Cohort study. Front Cell Infect Microbiol 9:467

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Brown MRD, Farquhar-Smith P (2016) Persistent pain in cancer survivors: pathogenesis and treatment options. Pain Clin Updat 24:1–8

    Google Scholar 

  100. Minarik J, Pavlicek P, Pour L, et al. (2015) Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One 10:e0123866

    Google Scholar 

  101. Richardson PG, Siegel DS, Vij R et al (2014) Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 123:1826–1832

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Hanaizi Z, Flores B, Hemmings R et al (2015) The European medicines agency review of Pomalidomide in Combination with low-dose Dexamethasone for the treatment of adult patients with multiple Myeloma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 20:329–334

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Luo J, Gagne JJ, Landon J, Avorn J, Kesselheim AS (2017) Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: a population-based cohort study. Eur J Cancer 70:22–33

    Article  CAS  PubMed  Google Scholar 

  104. Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458–3464

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Richardson PG, Weller E, Lonial S et al (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:679–686

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Siegel D, Martin T, Nooka A et al (2013) Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 98:1753–1761

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Grauer O, Wolff D, Bertz H et al (2010) Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: Report from the consensus conference on clinical practice in chronic graft-versus-host disease. Brain 133:2852–2865

    Article  PubMed  Google Scholar 

  108. Piccione EA, Salame K, Karirji B. Guillain-Barré Syndrome and Related Disorders (2014) In: Katirji B, Ruff RL, Kaminski HJ, eds. Neuromuscul Disord Clin Pract Springer, New York

    Google Scholar 

  109. Hughes RAC, Cornblath DR (2005) Guillain-Barré syndrome. Lancet 366:1653–1666

    Article  CAS  PubMed  Google Scholar 

  110. Lorenzoni PJ, Scola RH, Carsten ALM et al (2007) Chronic inflammatory demyelinating polyradiculoneuropathy in chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: case report. Arq Neuropsiquiatr 65:700–704

    Article  PubMed  Google Scholar 

  111. Gijtenbeek JMM, Van Den Bent MJ, Vecht CJ (1999) Cyclosporine neurotoxicity: a review. J Neurol 246:339–346

    Article  CAS  PubMed  Google Scholar 

  112. Farquhar-Smith P (2011) Chemotherapy-induced neuropathic pain. Curr Opin Support Palliat Care 5:1–7

    Article  PubMed  Google Scholar 

  113. Rison RA, Beydoun SR (2016) Paraproteinemic neuropathy: a practical review. BMC Neurol 16:13

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  114. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676

    Article  CAS  PubMed  Google Scholar 

  115. Matsuoka A, Maeda O, Mizutani T, et al. (2016) Bevacizumab exacerbates paclitaxel-induced neuropathy: a retrospective cohort study. PLoS One 11:e0168707

    Google Scholar 

  116. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799

    Article  CAS  PubMed  Google Scholar 

  117. Gopal AK, Ramchandren R, O’Connor OA et al (2012) Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 120:560–568

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Corbin ZA, Nguyen-Lin A, Li S et al (2017) Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. J Neurooncol 132:439–446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9:325–338

    Article  CAS  PubMed  Google Scholar 

  120. Dispenzieri A (2019) POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. Am J Hematol 94:812–827

    PubMed  Google Scholar 

  121. Pradat PF, Poisson M, Delattre JY (1994) Radiation-induced neuropathies: experimental and clinical data. Rev Neurol (Paris) 150:664–677

    CAS  Google Scholar 

  122. Delanian S, Lefaix JL (2004) The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol 73:119–131

    Article  PubMed  Google Scholar 

  123. Fallon MT. Neuropathic pain in cancer. Br J Anaesth [Internet] 2013; 111: 105–11 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23794652

  124. Delanian S, Lefaix JL, Pradat PF (2012) Radiation-induced neuropathy in cancer survivors. Radiother Oncol 105:273–282

    Article  PubMed  Google Scholar 

  125. Pierce SM, Recht A, Lingos TI et al (1992) Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 23:915–923

    Article  CAS  PubMed  Google Scholar 

  126. Taghian NR, Miller CL, Jammallo LS, O’Toole J, Skolny MN (2014) Lymphedema following breast cancer treatment and impact on quality of life: a review. Crit Rev Oncol Hematol 92:227–234

    Article  PubMed  Google Scholar 

  127. Feistner H, Weissenborn K, Münte TF, Heinze H‐J, Malin JP (1989) Post‐irradiation lesions of the caudal roots. Acta Neurol Scand 80: 277–81

    Google Scholar 

  128. Pritchard J, Anand P, Broome J et al (2001) Double-blind randomized phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy. Radiother Oncol 58:279–286

    Article  CAS  PubMed  Google Scholar 

  129. Patel V, McGurk M (2017) Use of pentoxifylline and tocopherol in radiation-induced fibrosis and fibroatrophy. Br J Oral Maxillofac Surg 55:235–241

    Article  CAS  PubMed  Google Scholar 

  130. Delanian S, Lefaix JL, Maisonobe T, Salachas F, Pradat PF (2008) Significant clinical improvement in radiation-induced lumbosacral polyradiculopathy by a treatment combining pentoxifylline, tocopherol, and clodronate (Pentoclo). J Neurol Sci 275:164–166

    Article  CAS  PubMed  Google Scholar 

  131. De Felice F, Musio D, Tombolini V (2016) Osteoradionecrosis and intensity modulated radiation therapy: an overview. Crit Rev Oncol Hematol 107:39–43

    Article  PubMed  Google Scholar 

  132. Wong CS, Fehlings MG, Sahgal A (2015) Pathobiology of radiation myelopathy and strategies to mitigate injury. Spinal Cord 53:574–580

    Article  CAS  PubMed  Google Scholar 

  133. Naidu MUR, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P (2004) Chemotherapy-induced and/or radiation therapy-induced oral mucositis—complicating the treatment of cancer. Neoplasia 6:423–431

    Article  PubMed  PubMed Central  Google Scholar 

  134. Maria OM, Eliopoulos N, Muanza T (2017) Radiation-Induced Oral Mucositis. Front Oncol 7:89

    Article  PubMed  PubMed Central  Google Scholar 

  135. Karlsson L, Quinlan D, Guo D et al (2004) Mobilized blood cells vs bone marrow harvest: experience compared in 171 donors with particular reference to pain and fatigue. Bone Marrow Transplant 33:709–713

    Article  CAS  PubMed  Google Scholar 

  136. Heary RF, Schlenk RP, Sacchieri TA et al (2002) Persistent iliac crest donor site pain: independent outcome assessment. Neurosurgery 50:510–517

    PubMed  Google Scholar 

  137. Kuendgen A, Fenk R, Bruns I et al (2006) Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 38:69–70

    Article  CAS  PubMed  Google Scholar 

  138. Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A (2006) Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. Haematologica 91:ECR08

    Google Scholar 

  139. Martino M, Morabito F, Console G et al (2003) Differences in transplant-related complications between hematologic malignancies and solid tumors receiving high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Tumori 89:385–390

    Article  PubMed  Google Scholar 

  140. Wang EH, Chen YA, Corringham S et al (2004) High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 34:581–587

    Article  CAS  PubMed  Google Scholar 

  141. Ferrara F, Palmieri S, De Simone M et al (2005) High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol 128:234–241

    Article  CAS  PubMed  Google Scholar 

  142. Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW (2013) Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis 19:327–346

    Article  CAS  PubMed  Google Scholar 

  143. Cheuk DKL, Lee TL, Chiang AKS, Ha SY, Lau YL, Chan GCF (2007) Risk factors and treatment of hemorrhagic cystitis in children who underwent hematopoietic stem cell transplantation. Transpl Int 20:73–81

    Article  PubMed  Google Scholar 

  144. Niscola P, Romani C, Scaramucci L et al (2008) Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Bone Marrow Transplant 41:757–764

    Article  CAS  PubMed  Google Scholar 

  145. Coppell JA, Richardson PG, Soiffer R et al (2010) Hepatic Veno-Occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 16:157–168

    Article  PubMed  Google Scholar 

  146. Akpek G, Chinratanalab W, Lee LA et al (2003) Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant 9:46–51

    Article  PubMed  Google Scholar 

  147. Treister NS, Woo S Bin, O’Holleran EW, Lehmann LE, Parsons SK, Guinan EC (2005) Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11:721–31

    Google Scholar 

  148. Couriel DR, Beguelin GZ, Giralt S et al (2002) Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. Bone Marrow Transplant 30:543–546

    Article  CAS  PubMed  Google Scholar 

  149. Socié G, Ritz J (2014) Current issues in chronic graft-versus-host disease. Blood 124:374–384

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  150. Offidani M, Corvatta L, Olivieri A et al (2001) A predictive model of Varicella-Zoster virus infection after autologous peripheral blood progenitor cell transplantation. Clin Infect Dis 32:1414–1422

    Article  CAS  PubMed  Google Scholar 

  151. Koc Y, Miller KB, Schenkein DP et al (2000) Varicella Zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 6:44–49

    Article  CAS  PubMed  Google Scholar 

  152. Galvin JP, Paice J, Mehta J (2015) Pain following hematopoietic stem cell transplant: a prospective observational study. Biol Blood Marrow Transplant 21:S249–S250

    Article  Google Scholar 

  153. Beckwée D, Leysen L, Meuwis K, Adriaenssens N (2017) Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis. Support Care Cancer 25:1673–1686

    Article  PubMed  Google Scholar 

  154. Laroche F, Perrot S, Medkour T, et al. (2017) Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study. PLoS One 12:e0187165

    Google Scholar 

  155. Din OS, Dodwell D, Wakefield RJ, Coleman RE (2010) Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat 120:525–538

    Article  CAS  PubMed  Google Scholar 

  156. Riley JL, Robinson ME, Wise EA, Price D (1999) A meta-analytic review of pain perception across the menstrual cycle. Pain 81:225–235

    Article  PubMed  Google Scholar 

  157. Khan QJ, Reddy PS, Kimler BF et al (2010) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119:111–118

    Article  CAS  PubMed  Google Scholar 

  158. Shapiro AC, Adlis SA, Robien K et al (2016) Randomized, blinded trial of vitamin D 3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Breast Cancer Res Treat 155:501–512

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  159. Morales L, Pans S, Paridaens R et al (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 104:87–91

    Article  CAS  PubMed  Google Scholar 

  160. Lintermans A, van Calster B, van Hoydonck M et al (2011) Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol 22:1763–1769

    Article  CAS  PubMed  Google Scholar 

  161. Janssen YJH, Helmerhorst F, Frölich M, Roelfsema F (2000) A switch from oral (2 mg/Day) to transdermal (50 μg/Day) 17β-Estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency. J Clin Endocrinol Metab 85:464–467

    CAS  PubMed  Google Scholar 

  162. Crew KD, Greenlee H, Capodice J et al (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877–3883

    Article  PubMed  Google Scholar 

  163. Mao JJ, Stricker C, Bruner D et al (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115:3631–3639

    Article  CAS  PubMed  Google Scholar 

  164. Smith I, Yardley D, Burris H et al (2017) Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final results of the randomized phase III femara versus anastrozole clinical evaluation. J Clin Oncol 35:1041–1048

    Article  CAS  PubMed  Google Scholar 

  165. Henry NL, Giles JT, Ang D et al (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111:365–372

    Article  CAS  PubMed  Google Scholar 

  166. Fontaine C, Meulemans A, Huizing M et al (2008) Tolerance of adjuvant letrozole outside of clinical trials. Breast 17:376–381

    Article  CAS  PubMed  Google Scholar 

  167. Cuzick J, Sestak I, Cella D, Fallowfield L (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9:1143–1148

    Article  CAS  PubMed  Google Scholar 

  168. Ziller V, Kalder M, Albert US et al (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20:431–436

    Article  CAS  PubMed  Google Scholar 

  169. Henry NL, Unger JM, Schott AF et al (2018) Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol 36:326–332

    Article  CAS  PubMed  Google Scholar 

  170. Coombes R, Kilburn L, Snowdon C et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559–570

    Article  CAS  PubMed  Google Scholar 

  171. Laroche M, Seniow M, Roché H, Ruyssen-Witrand A (2016) Arthralgia associated with autoimmune abnormalities under aromatase inhibitor therapy: outcome after cessation of treatment. J Rheumatol 43:1945–1946

    Article  CAS  PubMed  Google Scholar 

  172. Kubo M, Onishi H, Kuroki S et al (2012) Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res 32:2331–2336

    CAS  PubMed  Google Scholar 

  173. Yong CSM, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH (2017) CAR T-cell therapy of solid tumors. Immunol Cell Biol 95:356–363

    Article  CAS  PubMed  Google Scholar 

  174. Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127:3321–3330

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  175. Jadad AR, Browman GP (1995) The WHO analgesic ladder for cancer pain management: stepping up the quality of its evaluation. JAMA J Am Med Assoc 274:1870–1873

    Article  CAS  Google Scholar 

  176. Cronin-Fenton DP, Heide-Jørgensen U, Ahern TP et al (2015) Opioids and breast cancer recurrence: a Danish population-based cohort study. Cancer 121:3507–3514

    Article  CAS  PubMed  Google Scholar 

  177. O’Brien T, Christrup LL, Drewes AM et al (2017) European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain (United Kingdom) 21:3–19

    Google Scholar 

  178. Themistocleous AC, Ramirez JD, Serra J, Bennett DLH (2014) The clinical approach to small fiber neuropathy and painful channelopathy. Pract Neurol 14:368–379

    Article  PubMed  PubMed Central  Google Scholar 

  179. Paisley P, Serpell M (2017) The role of topiceuticals in cancer pain. Curr Opin Support Palliat Care 11:83–98

    Article  Google Scholar 

  180. Derry S, Wiffen PJ, Moore RA, Quinlan J (2014) Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev 7: CD010958

    Google Scholar 

  181. Baron R, Allegri M, Correa-Illanes G et al (2016) The 5% Lidocaine-Medicated plaster: its inclusion in international treatment guidelines for treating localized neuropathic pain, and clinical evidence supporting its use. Pain Ther 5:149–169

    Article  PubMed  PubMed Central  Google Scholar 

  182. Attal N, Cruccu G, Baron R et al (2010) EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 17:1113–1123

    Article  CAS  PubMed  Google Scholar 

  183. Finnerup NB, Attal N, Haroutounian S et al (2015) Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol 14:162–173

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  184. Derry S, Moore RA (2012) Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 9: CD010111

    Google Scholar 

  185. Derry S, Rice ASC, Cole P, Tan T, Moore RA (2017) Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2: CD007393

    Google Scholar 

  186. Fallon MT, Storey DJ, Krishan A et al (2015) Cancer treatment-related neuropathic pain: proof of concept study with menthol—a TRPM8 agonist. Support Care Cancer 23:2769–2777

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  187. Thompson DF, Brooks KG (2015) Systematic review of topical amitriptyline for the treatment of neuropathic pain. J Clin Pharm Ther 40:496–503

    Article  CAS  PubMed  Google Scholar 

  188. Wrzosek A, Woron J, Dobrogowski J, Jakowicka-Wordliczek J, Wordliczek J (2015) Topical clonidine for neuropathic pain. Cochrane Database Syst Rev 8: DC010967

    Google Scholar 

  189. Sawynok J (2014) Topical and peripheral ketamine as an analgesic. Anesth Analg 119:170–178

    Article  CAS  PubMed  Google Scholar 

  190. Hershman DL, Lacchetti C, Dworkin RH et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol 32:1941–1967

    Article  CAS  PubMed  Google Scholar 

  191. Rice ASC, Dworkin RH, McCarthy TD, et al ( 2014) EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: A randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet

    Google Scholar 

  192. Nascimento OJM, Pessoa BL, Orsini M et al (2016) Neuropathic pain treatment: Still a challenge. Neurol Int 8:6322

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  193. Patrick DL, Cleeland CS, von Moos R et al (2015) Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Support Care Cancer 23:1157–1168

    Article  PubMed  Google Scholar 

  194. Sopata M, Katz N, Carey W et al (2015) Efficacy and safety of tanezumab in the treatment of pain from bone metastases. Pain 156:1703–1713

    Article  CAS  PubMed  Google Scholar 

  195. Porta-Sales J, Garzón-Rodríguez C, Llorens-Torromé S, Brunelli C, Pigni A, Caraceni A (2017) Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project. Palliat Med 31:5–25

    Article  PubMed  Google Scholar 

  196. Chang DS, Hsu E, Hottinger DG, Cohen SP (2016) Anti-nerve growth factor in pain management: current evidence. J Pain Res 9:373–383

    CAS  PubMed  PubMed Central  Google Scholar 

  197. Liu XJ, Gingrich JR, Vargas-Caballero M et al (2008) Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex. Nat Med 14:1325–1332

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  198. De Felice M, Lambert D, Holen I, Escott KJ, Andrew D (2016) Effects of Src-kinase inhibition in cancer-induced bone pain. Mol Pain 12:1744806916643725

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  199. Danson S, Mulvey MR, Turner L, et al (2019) An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. J Bone Oncol 19:100261

    Google Scholar 

  200. Khan OA, Brinjikji W, Kallmes DF (2014) Vertebral augmentation in patients with multiple myeloma: a pooled analysis of published case series. Am J Neuroradiol 35:207–210

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  201. Nas ÖF, İnecikli MF, Hacıkurt K et al (2016) Effectiveness of percutaneous vertebroplasty in patients with multiple myeloma having vertebral pain. Diagnostic Interv Radiol 22:263–268

    Article  Google Scholar 

  202. Geurts JW, Joosten EA, Van Kleef M (2017) Current status and future perspectives of spinal cord stimulation in treatment of chronic pain. Pain 158:771–774

    Article  PubMed  Google Scholar 

  203. De Vos CC, Meier K, Zaalberg PB et al (2014) Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain 155:2426–2431

    Article  PubMed  Google Scholar 

  204. Cata JP, Cordella JV, Burton AW, Hassenbusch SJ, Weng HR, Dougherty PM (2004) Spinal cord stimulation relieves chemotherapy-induced pain: a clinical case report. J Pain Symptom Manage 27:72–78

    Article  PubMed  Google Scholar 

  205. Peng L, Min S, Zejun Z, Wei K, Bennett MI (2015) Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev 6:CD009389

    Google Scholar 

  206. Stearns LM, Abd-Elsayed A, Perruchoud C et al (2020) Intrathecal drug delivery systems for cancer pain: an analysis of a prospective. Multicenter Product Surveillance Registry. Anesth Analg 130:289–297

    PubMed  Google Scholar 

  207. Smith TJ, Coyne PJ, Staats PS et al (2005) An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol 16:825–833

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK

    Matthew R. D. Brown & Paul Farquhar-Smith

  2. The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK

    David J. Magee

Authors
  1. Matthew R. D. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Farquhar-Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David J. Magee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David J. Magee .

Editor information

Editors and Affiliations

  1. Departments of Supportive Care Medicine and Anesthesiology, City of Hope National Medical Center, Duarte, CA, USA

    Andrew Leitner

  2. New York, NY, USA

    Christine Chang

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Brown, M.R.D., Farquhar-Smith, P., Magee, D.J. (2021). Pain in the Cancer Survivor. In: Leitner, A., Chang, C. (eds) Fundamentals of Cancer Pain Management. Cancer Treatment and Research, vol 182. Springer, Cham. https://doi.org/10.1007/978-3-030-81526-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-81526-4_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-81525-7

  • Online ISBN: 978-3-030-81526-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation